Karl Maria Schumacher

Title: Karl Maria Schumacher: Innovator in Pharmaceutical Combination Therapy

Introduction

Karl Maria Schumacher is a notable inventor based in Darmstadt, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the area of cancer treatment. His innovative approach to combination therapy has the potential to enhance therapeutic outcomes for patients.

Latest Patents

Karl Maria Schumacher holds 1 patent related to a pharmaceutical combination. This invention involves an alpha-isoform specific phosphatidylinositol 3-kinase inhibitor compound, such as (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide), or a pharmaceutically acceptable salt thereof. The patent also includes an insulin-like growth factor-1 receptor (IGF1R) inhibitor, which can be used in combination for treating cancer. This innovative combination aims to provide effective treatment options for patients in need.

Career Highlights

Throughout his career, Karl Maria Schumacher has worked with prominent companies in the pharmaceutical industry. Notably, he has been associated with Novartis AG and Amgen Inc. His work in these organizations has allowed him to contribute to groundbreaking research and development in the field of medicine.

Collaborations

Karl has collaborated with esteemed colleagues, including Xizhong Huang and Malte Peters. These partnerships have fostered a collaborative environment that encourages innovation and the advancement of pharmaceutical therapies.

Conclusion

Karl Maria Schumacher is a distinguished inventor whose work in combination therapy has the potential to revolutionize cancer treatment. His contributions to the pharmaceutical industry reflect a commitment to improving patient outcomes through innovative solutions.